The goal of this observational study is to investigate the incidence, current management practices, and outcomes in pediatric patients with HAC after liver transplantation.
Research question:
What are the overall incidence of HAC and the effectiveness of all treatment strategies for HAC after pediatric LT?
What are the current management practices in the experience of centers, anticoagulant therapy, screening protocol, and assessment criteria for HAC after pediatric LT?
The burden of participation is considered to be minimal, and limited to the questionnaires.

开始日期2023-09-28

申办/合作机构

University Medical Center Groningen

[+21]

NCT06062706 / Enrolling by invitationN/AIIT

Comparison of Outcomes in Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy: A Single Center Prospective Registry Study

This will be a study to examine the outcomes of open, laparoscopic, and robotic Living Donor Liver Transplantation (LDLT) procedures. The analysis will encompass 3,448 cases (1,724 donor-recipient pairs) from January 2011 to March 2023, documenting the transition between these surgical techniques, with a noted crossover in 2018.

开始日期2023-08-06

申办/合作机构

King Faisal Specialist Hospital & Research Centre

NCT06056167 / CompletedN/AIIT

The Efficacy and Safety of Degludec Insulin Use for Glycemic Control in Critically Ill Patients: A Prospective Interventional Study (Protocol)

Background:
Dysglycemia in critically ill patients is common, where 40% to 54% of patients were found to be hyperglycemic on intensive care unit admission. Several randomized controlled trials (RCT) were conducted to address the importance of glycemic control during critical illness on patient's outcomes.
The American association of diabetes recommends initiation of insulin infusion for critically ill patients aiming to target glucose levels 140-180 mg/dl. However, several limitations prevent the use of insulin infusion in critically ill such as the requirements of frequent blood glucose measurement and nursing staff workload, which in turn led to the use of the subcutaneous rapid acting and basal insulin during critical illness. The evidence on the use of subcutaneous insulin therapy compared to insulin infusion is mainly derived from observational studies that showed conflicting results.
Multiple RCTs demonstrated the comparable efficacy of degludec versus glargine in blood glycemic control and better safety profile in terms of nocturnal hypoglycemia and severe hypoglycemia in the outpatient/inpatient diabetic population. Studies addressing the role, safety, and efficacy of degludec in critically ill patients are lacking.
Study aim:
To assess the effectiveness of using insulin degludec as basal insulin in conjunction with subcutaneous regular insulin sliding scale (ISS) in the glycemic control in critically ill patients.

开始日期2023-05-17

申办/合作机构

King Faisal Specialist Hospital & Research Centre

100 项与 King Faisal Specialist Hospital & Research Centre 相关的临床结果

登录后查看更多信息

0 项与 King Faisal Specialist Hospital & Research Centre 相关的专利（医药）

登录后查看更多信息

7,950

项与 King Faisal Specialist Hospital & Research Centre 相关的文献（医药）

2025-01-01·Annals of Hepatology

Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region

Article

作者: Nader, Fatema ; Alqahtani, Saleh A. ; Younossi, Zobair M ; Sanai, Faisal M ; Abaakhail, Faisal ; Alghamdi, Saad ; Stepanova, Maria ; Younossi, Zobair M. ; Yilmaz, Yusuf ; Al-Hamoudi, Waleed K. ; Alqahtani, Saleh A ; Alswat, Khalid ; Sanai, Faisal M. ; El-Kassas, Mohamed ; Mawardi, Mohamed ; Al-Hamoudi, Waleed K

INTRODUCTION AND OBJECTIVES:

Given the substantial burden of metabolic dysfunction-associated steatotic liver disease (MASLD), there is an urgent need to assess knowledge and awareness levels among physicians. We assessed MASLD knowledge among healthcare providers from Saudi Arabia, Egypt, and Türkiye.

MATERIALS AND METHODS:

Two global surveys containing 54-59 items assessed awareness and knowledge of MASLD/NAFLD- one was for hepatologists and gastroenterologists, and the second was for non-specialists (e.g. endocrinologists, primary care providers [PCPs], and other healthcare professionals). Data were collected using an electronic data collection form. Knowledge scores and variables associated with higher knowledge scores were compared across all specialties.

RESULTS:

A total of 584 physicians completed the survey (126 hepatologists, 178 gastroenterologists (GEs), 38 endocrinologists, 242 PCPs/others). Practice guidelines were the primary source for knowledge across all specialties (43-51%), then conferences (24-31%) except PCPs/others who selected the internet as the second common source (25%). Adherence to societal guidelines varied by specialty (81-84% of specialists vs 38-51% of non-specialists). Hepatologists and GEs showed similar mean knowledge scores (51-72% correct answers across three knowledge domains, p > 0.05); endocrinologists outperformed PCPs/others in knowledge scores in all knowledge domains, including Epidemiology/Pathogenesis (72% vs. 60%), Diagnostics (73% vs. 67%), and Treatment (78% vs. 67%) (all p < 0.01). Hospital-based practice and seeing a greater number of patients with MASLD/NAFLD were identified as independent predictors of higher knowledge scores among specialists (both p < 0.05).

CONCLUSIONS:

A knowledge gap in the identification, diagnosis, and management of MASLD/NAFLD was found despite the growing burden of MASLD/NAFLD in Saudi Arabia, Egypt, and Türkiye. Education to increase awareness is needed.

2024-12-31·RNA biology

Post-transcriptional regulation of BIRC5/survivin expression and induction of apoptosis in breast cancer cells by tristetraprolin

Article

作者: Moghrabi, Walid ; Al-Saif, Maher ; Khabar, Khalid S A ; Al-Ghamdi, Maha ; Al-Souhibani, Norah ; Al-Yahya, Suhad

Inhibition of apoptosis is one of the hallmarks of cancer and is a target of various therapeutic interventions. BIRC5 is an inhibitor of apoptosis that is aberrantly expressed in cancer leading to sustained growth of tumours. Post-transcriptional control mechanisms involving RNA-binding proteins and AU-rich elements (AREs) are fundamental to many cellular processes and changes in the expression or function of these proteins can promote an aberrant and pathological phenotype. BIRC5 mRNA has an ARE in its 3' UTR making it a candidate for regulation by the RNA binding proteins tristetraprolin (TTP) and HuR (ELAVL1). In this study, we investigated the binding of TTP and HuR by RNA-immunoprecipitation assays and found that these proteins were associated with BIRC5 mRNA to varying extents. Consequently, BIRC5 expression decreased when TTP was overexpressed and apoptosis was induced. In the absence of TTP, BIRC5 mRNA was stabilized, protein expression increased and the number of apoptotic cells declined. As an ARE-mRNA stabilizing protein, recombinant HuR led to upregulation of BIRC5 expression, whereas HuR silencing was concomitant with downregulation of BIRC5 mRNA and protein and increased cell death. Survival analyses demonstrated that increased TTP and low BIRC5 expression predicted an overall better prognosis compared to dysregulated TTP and high BIRC5. Thus, the results present a novel target of ARE-mediated post-transcriptional regulation.

2024-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Expert consensus on unmet needs, referral criteria and treatment goals for hidradenitis suppurativa in Saudi Arabia

Article

作者: Eshmawi, Maysa T. ; Madani, Abdulaziz ; Al-Faraidy, Nadya ; Alsantali, Adel ; Binamer, Yousef ; Bechara, Falk G. ; Fatani, Mohammed ; Alotaibi, Hend ; Alharithy, Ru’aa ; Almohanna, Hind M. ; Yousef Al-Mudaiheem, Hajer ; H. Al-Jedai, Ahmed ; Alajlan, Mohammed

Purpose: There is limited information about the diagnosis and treatment of hidradenitis suppurativa (HS) in the Kingdom of Saudi Arabia (KSA). This Delphi consensus study was conducted to develop recommendations for the management of HS in the KSA.Methods: The expert panel including 12 dermatologists with extensive experience treating HS patients provided nine consensus statements and recommendations on diagnosis and assessment, management, comorbidities and multidisciplinary approach, and education. The experts also developed clinical questions pertaining to the management of HS and rolled out as a survey to 119 dermatologists practising in the KSA.Results: The topics covered included: referring physicians' awareness of HS; referral criteria for HS; definition of moderate-to-severe HS; treatment goals; definition of treatment success; treatment and biologic initiation; comorbidities and multidisciplinary approach; patient education and awareness of HS. Full consensus (100%) from the expert dermatologists was received on all the topics except referring physicians' awareness of HS, definition of treatment success, and treatment and biologic initiation. The survey results resonated with the expert opinion.Conclusion: As HS is a chronic disease with negative impact on quality-of-life, timely diagnosis and treatment, early identification of comorbid conditions and a multidisciplinary care approach are crucial for effective management of HS.

项与 King Faisal Specialist Hospital & Research Centre 相关的新闻（医药）

2024-10-21

·PRNewswire

Global Health Exhibition Launches in Riyadh, Witnessing SAR 50 Billion in Investments on its First Day

RIYADH, Saudi Arabia, Oct. 21, 2024 /PRNewswire/ -- The seventh edition of the Global Health Exhibition has kicked off under the theme "Invest in Health" at the Riyadh International Convention and Exhibition Center in Mulham, north of Riyadh. The event is hosted under the patronage of the Ministry of Health, supported by the Health Sector Transformation Program, and organized by "Tahaluf" – a joint venture between the Saudi Federation for Cybersecurity, Programming, and Drones, Informa Global, and the Event Investment Fund. The exhibition will continue until October 23. During the opening ceremony, the Minister of Health, His Excellency Fahd bin Abdulrahman Al-Jalajel, highlighted the impact of health transformation in the sector, stating: "We aim to position Saudi Arabia as a hub for addressing current and future global challenges, following a unified government approach under Vision 2030. This is based on the principle of 'health in all policies' by developing regulations that encourage investment in innovation, building a healthcare system that unleashes the power of digital solutions and artificial intelligence, and developing local healthcare talent while attracting the best minds from around the world. These efforts are driving us forward in our health transformation with concrete and measurable steps." He added, "Today, we are proud of the World Health Organization's recognition of Saudi Arabia's elimination of trans fats from food products, placing the Kingdom at the forefront of countries receiving this distinction. Additionally, the WHO has announced that Saudi Arabia, represented by the Saudi Food and Drug Authority, is the first country in the region to achieve the highest 'maturity level 4' in the regulation of medicines and vaccines." Al-Jalajel also highlighted the expansion of the Saudi Board Program, which now offers 170 healthcare specialties, with 3,000 international practitioners enrolled. Speaking on investment opportunities, he said: "Investment in the healthcare sector continues to grow, with Saudi Arabia leading the region in healthcare investments. The largest public offering in the Saudi market this year was for Dr. Faqih Healthcare Group, preceded by the IPO of Dr. Sulaiman Al Habib Group, which was among the largest at the time, solidifying the healthcare sector as the fastest-growing in the Saudi market." He also noted the rapid growth of private health insurance, stating, "In 2011, only 3 million people had health insurance. By the end of 2023, that number had increased to over 12 million, with a market size of SAR 40 billion, expected to double by 2030." Al-Jalajel further announced the second generation of the "Takkad" centers, the digital twin feature within the "Sehhaty" app, as well as the inclusion of the Virtual Health Hospital in the Guinness World Records as the largest virtual hospital in the world. He also mentioned that exceptional international medical professionals have been granted the Premium Residency. The Global Health Exhibition witnessed investments exceeding SAR 50 billion, including notable announcements such as a SAR 4 billion pharmaceutical manufacturing deal between NUPCO, Novo Nordisk, and Sanofi, a SAR 5 billion expansion in Faqih Medical Group, and the construction of five primary care centers and two hospitals by Al Mousa Healthcare at a value of SAR 3 billion. The exhibition also announced Dallah's acquisition of Al Salam Hospital and Al Ahsa Hospital in the Eastern Province, adding a total of 749 beds, and the construction of a new Dallah Hospital in Riyadh with a 250-bed capacity and potential for expansion, valued at SAR 4 billion. On the sidelines of the exhibition, several agreements and partnerships were signed, including a partnership between the Council of Health Insurance and Alfaisal University, a memorandum of understanding between Imam Abdulrahman Bin Faisal University and the National Institute for Health Research, and an MoU between the Ministry of Health's Engineering and Supply Affairs Division and the National Center for Vegetation Cover and Combating Desertification. Additionally, MoUs were signed between the Ministry's National Health Command and Control Center and the Ministerial Committee for Traffic Safety, along with collaboration agreements between Lean Business Services and Elm, and between the Public Health Authority (Weqaya) and King Faisal Specialist Hospital and Research Center, among others. The exhibition opened with five key platforms: the Leadership Summit, Health Transformation Exhibition, Digital Health Exhibition, Medical Excellence Exhibition, and Investors' Exhibition. Other highlights include the NUPCO Health Innovation Hackathon, the "Next Generation Vision" competition for startups, and several unique experiences such as 3D medical diagnostics, the Medical Escape Room Challenge, and sporting activities, with prizes exceeding SAR 2 million awarded to attendees throughout the event. SOURCE Global Health Exhibition WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购IPO

2024-09-04

·PRNewswire

King Faisal Hospital Recognized for "Global Healthcare Impact" With C3 Summit Award Nomination

NEW YORK, Sept. 4, 2024 /PRNewswire/ -- The highly anticipated 13th annual C3 US-Arab Healthcare Summit is set to again take place in New York City on Monday, September 16, 2024 at the historic Union League Club in New York City under the umbrella theme Tech-Driven Healthcare Evolution & Breakthroughs: Addressing Future Global Challenges & Impact of Advanced Technologies. Dr. Björn Zoëga, MD PhD, Deputy Chief Executive Officer, King Faisal Specialist Hospital & Research Centre, will receive the 2024 C3 Davos of Healthcare™ Global Innovative Healthcare & Impact Transformation Award. This award recognizes a global leader who is focused on creating and implementing cutting-edge solutions that improve patient outcomes, enhance accessibility, and reduce costs while emphasizing sustainability and social responsibility. Saudi Arabia's King Faisal Specialist Hospital and Research Center (KFSHRC), who proudly joins C3 as both a Strategic Partner Sponsor and Scientific Committee Chair, headed by Dr. Edward J. Cupler, Executive Director of Research and Innovation, King Faisal Specialist Hospital and Research Centre , will be reinforcing the hospital's commitment to advancing global healthcare standards through international cooperation and knowledge transfer. This year's C3 Summit will emphasize innovation and collaboration across sectors, including healthcare, education, technology, and finance. The highly anticipated 13th annual C3 US-Arab Healthcare Summit is set to again take place in New York City on Monday, September 16, 2024 at the historic Union League Club in New York City under the umbrella theme Tech-Driven Healthcare Evolution & Breakthroughs: Addressing Future Global Challenges & Impact of Advanced Technologies. Held in collaboration with the United Nations General Assembly (UNGA), it is listed as the first official meeting in the Healthcare Category. Together with their new Strategic Partner, King Faisal Specialist Hospital & Research Centre, this year's C3 Summit is bringing together leaders from diverse industries to foster dialogue and partnerships that bridge the gap between the United States and the Arab world. Other keynote speakers at the event will include General David H. Petraeus, US Army (Ret.), Partner at KKR and Chairman of the KKR Global Institute, and Dr. Maan Fares, Chairman of Global Patient Services at the Cleveland Clinic and a C3 Board Advisor. Contact: Calli Heenan +1-732-859-5192 [email protected] SOURCE C3 Summit International

2024-07-01

·BioSpace

KFSHRC Performs Over 5,000 Successful Kidney Transplants

RIYADH, Saudi Arabia, July 01, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has successfully performed 5,000 kidney transplants since the inception of its Transplant Program in 1981, placing it among a select group of leading global health centres that have achieved this milestone. Last year alone, KFSHRC has performed 80 paediatric kidney transplants, the highest number conducted by any hospital in a single year. This achievement makes KFSHRC's Kidney Transplant Program the largest of its kind, surpassing health centres in the United States and Europe. Over the past decade, the program has experienced significant growth, with more than 3,000 transplants performed since 2010 and approximately 1,250 transplants in the last three years alone. Moreover, the establishment of the Kidney Paired Donation (KPD) program has significantly revolutionised the transplantation landscape by addressing the challenge of compatibility between patients and their donors. This program has helped patients who would otherwise face considerable obstacles in finding suitable matches. By facilitating the exchange of donors whose blood types or tissues do not match the intended recipient, KFSHRC has become a leader in paired donation transplants compared to any single health centres in the United States and Europe. Furthermore, by adopting advanced technologies, the centre now relies entirely on minimally invasive surgery including removing kidneys from donors with the robotic assistance. The surgeons are also able to transplant kidneys in a selected group of patients through robotic surgery. This minimally invasive procedure enhances precision and safety. It is important to note that the kidney and patient survival rates at one year are between 97% to 99%. This achievement underscores the establishment of a stellar transplant centre within the organisation. Beyond routine kidney transplants, this centre specialises in complex cases, including those involving different blood groups, low-weight paediatric patients, paired exchanges, and patients with elevated body mass index. KFSHRC has retained its status as the leading institution in the Middle East and Africa for the second year running and ranks 20th globally among the top 250 academic medical centres worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance. Additionally, Newsweek Magazine has ranked it among the top 250 hospitals globally. For further information, please contact: Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429 Mr. Abdullah Alown, Media Coordination Officer, 0556294232 A photo accompanying this announcement is available at KFSHRC Performs Over 5,000 Successful Kidney Transplants KFSHRC Performs Over 5,000 Successful Kidney Transplants

100 项与 King Faisal Specialist Hospital & Research Centre 相关的药物交易

登录后查看更多信息

100 项与 King Faisal Specialist Hospital & Research Centre 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

百里香醌 ( E2F1 x MUC4 x PTEN )	弥漫性大B细胞淋巴瘤更多	临床前
rAAV2-VMD2-hMERTK(King Faisal Specialist Hospital & Research Center) ( MerTK )	视网膜色素变性更多	无进展